Hester Biosciences Reports Positive Financial Results for Q1 FY25

Hester Biosciences, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ended Jun 2024. The company has shown positive performance in terms of its financials, with a score improvement from -9 to 9 in the last 3 months.

One of the key highlights of the financial results is the company’s strong operating cash flow, which has been consistently growing over the last three years. This indicates that the company has been able to generate higher revenues from its business operations.

In addition, Hester Bios has also shown a positive trend in its operating profit (PBDIT) for the last five quarters, with the highest recorded at Rs 17.65 crore. This shows that the company’s efficiency has improved, leading to higher profits.

The profit before tax (PBT) less other income has also seen a positive trend, with the highest recorded at Rs 9.36 crore in the last five quarters. This has grown at a rate of 20.62% year on year, indicating a positive near-term trend.

The company’s debt-equity ratio has also been consistently decreasing over the last five half-yearly periods, indicating a reduction in borrowing as compared to equity capital. This is a positive sign for the company’s financial health.

However, one area of concern for Hester Bios is its net sales, which have shown a negative growth of -6.35% year on year. This indicates a negative near-term sales trend for the company.

Overall, Hester Biosciences has shown a positive financial performance in the quarter ended Jun 2024, with improvements in key areas such as operating cash flow, operating profit, and profit before tax. However, the company needs to address its declining net sales in order to sustain its growth in the future. Based on these financials, MarketsMOJO has given a ‘Hold’ call for Hester Bios stock.